All In MedTech

Device Trial Radar · NCT00713557

Shanghai Registry of Acute Coronary Events

Phase 4 Study to Compare Different Therapeutic Strategies for Patients With ACS

Last checked: Nov 19, 2026Latest source record: Oct 13, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

20,000

Planned (sponsor's estimate)

Start

Mar 2005

Primary completion

Jan 2018

Sponsor

Lead sponsor
Shanghai Jiao Tong University School of MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ministry of Science and Technology of the People´s Republic of China; Changhai Hospital
First posted
Jul 11, 2008

More device trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

SRACE is an multicenter observational database of outcomes for patients who are hospitalized with an acute coronary events. SRACE includes over 20 hospitals in Shanghai China that have enrolled a total of more than 3,000 patients since 2005, with an annual enrollment of 500 patients. The major purpose of the SRACE program is to evaluate the prognosis of patients admitted to the hospital due to acute coronary events, comparing different therapeutic strategies, in-hospital transferring system, and so on. All participating physicians receive confidential quarterly reports showing ther outcomes side-by-side with the aggregate outcomes of all participating hospitals.

Conditions

  • Coronary Artery Disease
  • Acute Coronary Syndrome

Interventions

  • drug-eluting stentDevice

    drug-eluting stent, including sirolimus-eluting, paclitaxel-eluting and other types of China-made drug-eluting stent

  • TirofibanDrug

    upstream (in emergency room) versus downstream (in catheterization lab) intra-coronary loading versus conventional intravenous loading

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. major adverse cardiac events(MACE), including death, non-fatal re-MI, and target vessel revascularizationTime frame: in-hospital, 30d, and long-term follow-up

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Dept. of Cardiology, Ruijin Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.